Intracranial Aneurysm Treatment Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The intracranial aneurysm treatment devices market size was valued at USD 1.72 billion in 2025 and is estimated to grow from USD 1.89 billion in 2026 to reach USD 3.03 billion by 2031, at a CAGR of 9.90% during the forecast period (2026-2031). This report is Segmented by Device Type (Embolization Coils, Flow Diverters, Intrasaccular Flow Disruptors, Intracranial Stents & Balloons, and More), End User (Hospitals, Ambulatory Surgical Centers, Specialty Neurosurgical Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Intracranial Aneurysm Treatment Devices Market Trends and Insights

Rising Demand for Minimally Invasive Endovascular Procedures

Outpatient-ready flow diverters and AI-guided robotic systems have made complex neurovascular work feasible in ambulatory environments. In 2024, US ambulatory surgical centers treated 3.3 million Medicare beneficiaries, signaling a decisive swing away from inpatient neurosurgery. Robotic deployments such as the CorPath GRX platform secured 100% technical success and lower radiation exposure, encouraging health systems to open dedicated outpatient neuro-intervention suites.

Growing Prevalence of Unruptured Aneurysm Detection Through Incidental Brain Imaging

High-resolution MRI and CT angiography now uncover countless asymptomatic lesions, expanding the treatable population. AI algorithms like Viz ANEURYSM, cleared by the FDA in 2024, standardize reading protocols and reduce inter-observer variability. The surge strains risk-stratification workflows and stimulates demand for decision-support tools bundled with next-generation devices.

High Device & Procedural Costs With Limited Reimbursement

US CMS pass-through codes remain restrictive for cutting-edge implants, while Korea reimburses flow diverters only for large aneurysms, capping penetration. Manufacturers now pair launches with health-economic dossiers and risk-sharing contracts to prove lifetime value to payers.

Other drivers and restraints analyzed in the detailed report include:

• Age-Linked Hypertension & Smoking Prevalence in Developing Economies
• FDA Breakthrough-Device Designations Accelerating Device Approvals
• Shortage Of Dual-Trained Endovascular Neurosurgeons in Emerging Markets

Segment Analysis

Flow diverters occupy the fastest lane, expanding at a 14.0% CAGR through 2031 and steadily eroding coil dominance. The Pipeline Vantage recorded 81.7% six-month occlusion in pivotal studies, while hydrophilic-coated variants cut thrombotic events to 4.7% and achieved 92.3% long-term closure. Platinum remains central, forming 30-40% of material content for its radiopacity and biocompatibility.

The segment’s outlook is strengthened by intrasaccular disruptors such as WEB 17 that produce 86.5% complete occlusion in ruptured aneurysms after one year. As a result, global purchasers are reallocating capital budgets toward devices promising fewer retreatments and shorter learning curves, uplifting the intracranial aneurysm treatment devices market.

Complete Report Scope:

• By Device Type
  • Embolization Coils
  • Flow Diverters
  • Intrasaccular Flow Disruptors
  • Intracranial Stents & Balloons
  • Aneurysm Clips
  • Others
• By End-user
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Neurosurgical Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America sustained a 41.3% revenue share in 2025, aided by FDA breakthrough pathways and payer openness to premium implants. Corporate M&A remains brisk, exemplified by Stryker’s USD 4.9 billion Inari acquisition that broadens access to venous and neurovascular segments. Nonetheless, device review staffing cuts at the FDA risk stretching approval queues, tempering near-term acceleration.

Asia-Pacific is the fastest-growing region with an 11.2% CAGR through 2031. China’s NMPA reforms and the “Healthy China 2030” mandate increase funding for cerebrovascular care, whereas Japan’s PMDA provides predictable, science-based approvals. Growing middle-class demand, combined with policy support, expands the intracranial aneurysm treatment devices market, though heterogeneous reimbursement keeps price tiers wide.

Europe’s MDR environment remains rigorous, emphasizing long-term safety data. Penumbra’s 2024 CE marks for aspiration and coil systems show that novel devices can still navigate the pathway when supported by robust clinical evidence. Brexit-related divergence obliges firms to budget separately for UK conformity, nudging some smaller entrants to prioritize EU27 first.

List of Companies Covered in this Report:

• Stryker
• Medtronic
• Johnson & Johnson (CERENOVUS)
• Terumo Neuro
• MicroPort
• Penumbra
• Balt Extrusion S.A.
• Phenox
• B. Braun
• Integra LifeSciences
• Adeor Medical
• Sequent Medical
• Wallaby Medical
• Rapid Medical
• Evasc Neurovascular
• Kaneka Medix
• Cerus Endovascular
• Ceremedix (Boston Scientific spin-out)
• Route 92 Medical
• MicroVasx
• Codman Neuro

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support